Patents by Inventor Lisa Wei
Lisa Wei has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240084407Abstract: The invention provides a transgenic Glycine max event MON87751, plants, plant cells, seeds, plant parts, progeny plants, and commodity products comprising event MON87751. The invention also provides polynucleotides specific for event MON87751, plants, plant cells, seeds, plant parts, and commodity products comprising polynucleotides for event MON87751. The invention also provides methods related to event MON87751.Type: ApplicationFiled: August 11, 2023Publication date: March 14, 2024Inventors: Kim A. Beazley, Wen C. Burns, Robert H. Cole, II, Ted C. MacRae, John A. Miklos, Lisa G. Ruschke, Kairong Tian, Liping Wei, Kunsheng Wu
-
Publication number: 20210269827Abstract: The invention provides a replication-deficient serotype 28 adenoviral vector characterized by comprising a portion of a serotype 45 adenoviral hexon protein and/or a portion of a serotype 45 fiber protein in place of the endogenous serotype 28 hexon and/or fiber protein.Type: ApplicationFiled: March 12, 2021Publication date: September 2, 2021Applicant: GenVec, Inc.Inventors: Lisa Wei, Douglas E. Brough, C. Richter King
-
Patent number: 10947560Abstract: The invention provides a replication-deficient serotype 28 adenoviral vector characterized by comprising a portion of a serotype 45 adenoviral hexon protein and/or a portion of a serotype 45 fiber protein in place of the endogenous serotype 28 hexon and/or fiber protein.Type: GrantFiled: September 11, 2017Date of Patent: March 16, 2021Assignee: GenVec, Inc.Inventors: Lisa Wei, Douglas E. Brough, C. Richter King
-
Publication number: 20190100561Abstract: Herpes Simplex Virus (HSV) antigens that elicit an HSV-specific immune response and can be used to treat or prevent HSV infection are provided. Nucleic acid sequences, polypeptides, vectors, and compositions, as well as methods to induce an immune response against HSV, treat or prevent HSV disease, induce a T cell response against HSV, and induce an antibody response against HSV also are provided.Type: ApplicationFiled: October 10, 2018Publication date: April 4, 2019Applicant: GenVec, Inc.Inventors: Lisa Wei, Douglas E. Brough, Christopher Lazarski
-
Patent number: 10125174Abstract: Herpes Simplex Virus (HSV) antigens that elicit an HSV-specific immune response and can be used to treat or prevent HSV infection are provided. Nucleic acid sequences, polypeptides, vectors, and compositions, as well as methods to induce an immune response against HSV, treat or prevent HSV disease, induce a T cell response against HSV, and induce an antibody response against HSV also are provided.Type: GrantFiled: June 9, 2017Date of Patent: November 13, 2018Assignee: GenVec, Inc.Inventors: Lisa Wei, Douglas E. Brough, Christopher Lazarski
-
Publication number: 20180100164Abstract: The invention provides a replication-deficient serotype 28 adenoviral vector characterized by comprising a portion of a serotype 45 adenoviral hexon protein and/or a portion of a serotype 45 fiber protein in place of the endogenous serotype 28 hexon and/or fiber protein.Type: ApplicationFiled: September 11, 2017Publication date: April 12, 2018Applicant: GenVec, Inc.Inventors: Lisa Wei, Douglas E. Brough, C. Richter King
-
Patent number: 9790519Abstract: The invention provides a replication-deficient serotype 28 adenoviral vector characterized by comprising a portion of a serotype 45 adenoviral hexon protein and/or a portion of a serotype 45 fiber protein in place of the endogenous serotype 28 hexon and/or fiber protein.Type: GrantFiled: May 28, 2013Date of Patent: October 17, 2017Assignee: GenVec, Inc.Inventors: Lisa Wei, Douglas E. Brough, C. Richter King
-
Publication number: 20170275339Abstract: Herpes Simplex Virus (HSV) antigens that elicit an HSV-specific immune response and can be used to treat or prevent HSV infection are provided. Nucleic acid sequences, polypeptides, vectors, and compositions, as well as methods to induce an immune response against HSV, treat or prevent HSV disease, induce a T cell response against HSV, and induce an antibody response against HSV also are provided.Type: ApplicationFiled: June 9, 2017Publication date: September 28, 2017Applicant: GenVec, Inc.Inventors: Lisa Wei, Douglas E. Brough, Christopher Lazarski
-
Patent number: 9676824Abstract: Herpes Simplex Virus (HSV) antigens that elicit an HSV-specific immune response and can be used to treat or prevent HSV infection are provided. Nucleic acid sequences, polypeptides, vectors, and compositions, as well as methods to induce an immune response against HSV, treat or prevent HSV disease, induce a T cell response against HSV, and induce an antibody response against HSV also are provided.Type: GrantFiled: May 16, 2013Date of Patent: June 13, 2017Assignee: GenVec, Inc.Inventors: Lisa Wei, Douglas E. Brough, Christopher Lazarski
-
Publication number: 20150167018Abstract: The invention provides a replication-deficient serotype 28 adenoviral vector characterized by comprising a portion of a serotype 45 adenoviral hexon protein and/or a portion of a serotype 45 fiber protein in place of the endogenous serotype 28 hexon and/or fiber protein.Type: ApplicationFiled: May 28, 2013Publication date: June 18, 2015Inventors: Lisa Wei, Douglas E. Brough, C. Richter King
-
Publication number: 20150140025Abstract: Herpes Simplex Virus (HSV) antigens that elicit an HSV-specific immune response and can be used to treat or prevent HSV infection are provided. Nucleic acid sequences, polypeptides, vectors, and compositions, as well as methods to induce an immune response against HSV, treat or prevent HSV disease, induce a T cell response against HSV, and induce an antibody response against HSV also are provided.Type: ApplicationFiled: May 16, 2013Publication date: May 21, 2015Inventors: Lisa Wei, Douglas E. Brough, Christopher Lazarski
-
Publication number: 20090149381Abstract: The invention provides methods of inhibiting angiogenesis within a tissue, promoting neuron protection within a tissue, and treating a disease in a mammal, wherein (a) a gene transfer vector encoding a protein of a serpin superfamily or a therapeutic fragment or variant thereof or (b) a protein of a serpin superfamily or a therapeutic fragment or variant thereof is administered with an inhibitor of matrix metalloprotease (MMP). Alternatively, the method comprises administration of (a) a protein of a serpin superfamily or therapeutic fragment or variant thereof or (b) a gene transfer vector encoding a protein of a serpin superfamily or a therapeutic fragment or variant thereof, wherein the protein or nucleic acid encoding the protein comprises at least one mutation which renders the protein of the serpin superfamily resistant to cleavage by an MMP.Type: ApplicationFiled: October 10, 2008Publication date: June 11, 2009Applicant: GenVec, Inc.Inventors: Christopher Reiter, Miguel E. Carrion, Melissa M. Hamilton, Lisa Wei, C. Richter King
-
Publication number: 20090041759Abstract: The invention is directed to a method of delivering a gene product to an animal. The method comprises administering an expression vector comprising a nucleic acid sequence operably linked to a promoter and encoding a gene product, and upregulating transcription of the nucleic acid sequence in the ocular cell. The expression vector can be an adenoviral vector. The invention further provides a method of prophylactically or therapeutically treating an animal for at least one ocular-related disorder. The method comprises contacting an ocular cell with an expression vector comprising a nucleic acid sequence encoding an inhibitor of angiogenesis and/or a neurotrophic agent. In one aspect, the method further comprises upregulating transcription of the nucleic acid sequence. Preferably, if 2×108 adenoviral particles of the inventive method are administered to a mouse, the level of expression of the nucleic acid sequence is not diminished more than ten-fold at 28 days post-administration.Type: ApplicationFiled: May 12, 2008Publication date: February 12, 2009Applicant: GENVEC, INC.Inventors: Duncan L. McVey, Douglas E. Brough, Imre Kovesdi, Lisa Wei
-
Publication number: 20090018100Abstract: The present invention is directed to a method of prophylactically or therapeutically treating an animal for at least one ocular-related disorder, e.g., ocular neovascularization or age-related macular degeneration. The method comprises contacting an ocular cell with an expression vector comprising a nucleic acid sequence encoding an inhibitor of angiogenesis and the same or different nucleic acid sequence encoding a neurotrophic agent. The method also can comprise contacting an ocular cell with different expression vectors, each comprising a nucleic acid sequence encoding an inhibitor of angiogenesis and/or a nucleic acid sequence encoding a neurotrophic agent. In addition, the present invention provides a viral vector comprising a nucleic acid sequence encoding pigment epithelium-derived factor (PEDF) or a therapeutic fragment thereof.Type: ApplicationFiled: September 24, 2008Publication date: January 15, 2009Applicant: GenVec, Inc.Inventors: Imre Kovesdi, Douglas E. Brough, Lisa Wei, Duncan L. McVey
-
Publication number: 20070232541Abstract: The invention provides methods of inhibiting angiogenesis within a tissue, promoting neuron protection within a tissue, and treating a disease in a mammal, wherein (a) a gene transfer vector encoding a protein of a serpin superfamily or a therapeutic fragment or variant thereof or (b) a protein of a serpin superfamily or a therapeutic fragment or variant thereof is administered with an inhibitor of matrix metalloprotease (MMP). Alternatively, the method comprises administration of (a) a protein of a serpin superfamily or therapeutic fragment or variant thereof or (b) a gene transfer vector encoding a protein of a serpin superfamily or a therapeutic fragment or variant thereof, wherein the protein or nucleic acid encoding the protein comprises at least one mutation which renders the protein of the serpin superfamily resistant to cleavage by an MMP.Type: ApplicationFiled: May 18, 2007Publication date: October 4, 2007Applicant: GenVec, Inc.Inventors: Christopher Reiter, Miguel Carrion, Lisa Wei, Melissa Hamilton, C. King
-
Publication number: 20070098692Abstract: The present invention is directed to a method of prophylactically or therapeutically treating an animal for at least one ocular-related disorder, e.g., ocular neovascularization or age-related macular degeneration. The method comprises contacting an ocular cell with an expression vector comprising a nucleic acid sequence encoding an inhibitor of angiogenesis and the same or different nucleic acid sequence encoding a neurotrophic agent. The method also can comprise contacting an ocular cell with different expression vectors, each comprising a nucleic acid sequence encoding an inhibitor of angiogenesis and/or a nucleic acid sequence encoding a neurotrophic agent. In addition, the present invention provides a viral vector comprising a nucleic acid sequence encoding pigment epithelium-derived factor (PEDF) or a therapeutic fragment thereof.Type: ApplicationFiled: December 13, 2006Publication date: May 3, 2007Applicant: GenVec, Inc.Inventors: Imre Kovesdi, Douglas Brough, Lisa Wei, Duncan McVey
-
Publication number: 20050260180Abstract: The invention is directed to a method of prophylactically or therapeutically treating an animal for vascular leakage in an eye. The method comprises administering to an animal in need thereof an expression vector comprising a nucleic acid sequence encoding pigment epithelium-derived factor (PEDF) such that vascular leakage in the eye of the animal is treated prophylactically or therapeutically. The invention also provides a method of prophylactically or therapeutically treating an animal for vascular leakage in an eye. The method comprises periocularly administering to an animal in need thereof PEDF such that vascular leakage of the animal is treated prophylactically or therapeutically. The invention also provides a method of prophylactically or therapeutically treating an animal for non-diabetic vascular leakage in an eye. The method comprises administering to an animal in need thereof PEDF such that non-diabetic vascular leakage in the eye is treated prophylactically or therapeutically.Type: ApplicationFiled: March 11, 2005Publication date: November 24, 2005Applicant: GenVec, Inc.Inventors: Lisa Wei, Henrik Rasmussen
-
Publication number: 20050220768Abstract: The invention is directed to a method of delivering a gene product to an animal. The method comprises administering an expression vector comprising a nucleic acid sequence operably linked to a promoter and encoding a gene product, and upregulating transcription of the nucleic acid sequence in the ocular cell. The expression vector can be an adenoviral vector. The invention further provides a method of prophylactically or therapeutically treating an animal for at least one ocular-related disorder. The method comprises contacting an ocular cell with an expression vector comprising a nucleic acid sequence encoding an inhibitor of angiogenesis and/or a neurotrophic agent. In one aspect, the method further comprises upregulating transcription of the nucleic acid sequence. Preferably, if 2×108 adenoviral particles of the inventive method are administered to a mouse, the level of expression of the nucleic acid sequence is not diminished more than ten-fold at 28 days post-administration.Type: ApplicationFiled: May 26, 2005Publication date: October 6, 2005Applicant: GenVec, Inc.Inventors: Duncan McVey, Douglas Brough, Imre Kovesdi, Lisa Wei
-
Publication number: 20050101018Abstract: The present invention provides a viral vector comprising a nucleic acid sequence encoding pigment epithelium-derived factor (PEDF) or a therapeutic fragment thereof. The nucleic acid sequence is operably linked to regulatory sequences necessary for expression of PEDF or a therapeutic fragment thereof. Preferably, the viral vector is an adenoviral vector or an adeno-associated viral vector. Also preferably, the viral vector further comprises one or more additional nucleic acid sequences encoding therapeutic substances other than PEDF.Type: ApplicationFiled: October 14, 2004Publication date: May 12, 2005Applicant: GenVec, Inc.Inventors: Imre Kovesdi, Douglas Brough, Duncan McVey, Lisa Wei
-
Patent number: 6821775Abstract: The present invention provides a viral vector comprising a nucleic acid sequence encoding pigment epithelium-derived factor (PEDF) or a therapeutic fragment thereof. The nucleic acid sequence is operably linked to regulatory sequences necessary for expression of PEDF or a therapeutic fragment thereof. Preferably, the viral vector is an adenoviral vector or an adeno-associated viral vector. Also preferably, the viral vector further comprises one or more additional nucleic acid sequences encoding therapeutic substances other than PEDF.Type: GrantFiled: June 23, 2000Date of Patent: November 23, 2004Assignee: GenVec, Inc.Inventors: Imre Kovesdi, Douglas E. Brough, Duncan L. McVey, Lisa Wei